Izotropic Corporation announces the closing of a non-brokered private placement

VANCOUVER, BC – TheNewswire – April 4, 2022 – Izotropic Corporation (“Izotropic“or the”Company“) (CST:IAO) (CNSX:IAO.NC) (OTC:IZOZF) (ESF:1R3), a company marketing a dedicated breast CT (computed tomography) imaging platform, IzoView, for more precise detection and diagnosis of breast cancers, is pleased to announce, following its press release of March 30, 2022, that it has completed a non-brokered private placement (the “Offer“) unsecured promissory notes (each, a “To note“) pursuant to which the Company issued: (i) Notes purchased for an aggregate price of $2,050,000, and (ii) an aggregate of 826,613 detachable non-transferable stock warrants (each, a “To guarantee“), representing approximately 403.2 Warrants for every $1,000 Principal Amount of the Notes, with no Partial Warrants issued.

Each Warrant is exercisable into one ordinary share in the capital of the Company (each, a “Warrant action“) at an exercise price of $0.62 per warrant share for a period of two (2) years from the closing date.

The Notes will bear interest at the rate of 1% per month from the date of issue (the “Closing“), payable every three months. The Bonds will mature on the date falling one year after the date of issue (the “Due date“).

Proceeds from the offering will be used to complete the initial construction of the IzoView device, engage a clinical research organization to undertake the clinical study for FDA marketing clearance and working capital.

All securities issued under the Offering will be subject to a statutory hold period of four months and one day from the date of issue in accordance with applicable securities laws. The Company has not paid any finder’s fee in connection with the Offer.

None of the securities issued under the Offer will be registered under the United States Securities Act of 1933as amended (the “1933 Act“), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy or will there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

IN THE NAME OF THE COMPANY
Dr. John McGraw, CEO

Contact with Investor Relations:
Jacques Berard
E-mail: jberard@izocorp.com
Cell: 778-228-2314
Toll free: 1-833-IZOCORP ext. 1

Contact for media inquiries:
Jaclyn Thast
E-mail: jaclyn@izocorp.com
Toll free: 1-833-IZOCORP ext. 3

About Izotropic Corporation

Izotropic Corporation is the only publicly traded company to market a dedicated breast CT imaging platform, IzoView, for more accurate breast cancer detection and diagnosis. To accelerate patient and provider access to IzoView, Izotropic’s initial clinical study aims to demonstrate the superior performance of diagnostic CT imaging of the breast compared to diagnostic mammography procedures and will be launched in the second quarter of 2022. In follow-up clinical studies, Izotropic intends to validate applications of the platform, including radiology screening, treatment planning and monitoring in surgical oncology, breast reconstruction and implant monitoring in plastic surgery and reconstructive.

More information about Izotropic Corporation can be found on its website at izocorp.com and by consulting its profile on SEDAR at sedar.com.

Forward-looking statements

This document may contain statements that are “forward-looking statements”, which are based on management’s current estimates, assumptions, projections and expectations of the business and its knowledge of the relevant market and economic environment in which it operates. . The Company has tried, to the extent possible, to identify such information and statements by using words such as “anticipate”, “believe”, “intend”, “estimate”, “expect”, “have the ‘intent to’, ‘may’, ‘plan’, ‘predict’, ‘project’, ‘target’, ‘potential’, ‘shall’, ‘should’, ‘could’, ‘should’, ‘continue’, ‘contemplate’ and other similar expressions and their derivatives in connection with any discussion of future events, trends or prospects or of future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such may cause future results of the Company’s business to differ materially from the contents and implications of these statements. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of future events or circumstances. , unless otherwise stated. by the law. Neither the Company nor its shareholders, officers and consultants shall be responsible for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing herein should be taken as medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO US NEWS WIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

Copyright (c) 2022 TheNewswire – All Rights Reserved.